Biovica strengthens its management

Uppsala, Sweden, February 20, 2017. Biovica has strengthened its management team to ensure continued successful development. Cecilia Driving (CFO), Karin Mattsson (R&D Director) and Johanna Faris (Quality and Regulatory Assurance Director) have joined the company.

Cecilia Driving holds a dual degree in BA and law. She has held several CFO positions in life science, private equity, research and telecom companies. Her previous experience includes IPO processes and working in publicly-listed companies. Cecilia is also a board member of Acreo Swedish ICT AB.

Karin Mattsson holds a PhD in Cell- and Tumor Biology from the Karolinska Institutet. She has over 20 years’ industrial experience, including roles as product manager and R&D Director at Olerup SSP, a company that develops, manufactures and markets in vitro diagnostic products in Europe and the United States. Karin has successfully contributed to the development and commercialization of these products.

Johanna Faris has extensive experience of ISO 13485 and QSR quality standards, as well as worldwide product registration. In her most recent role as Quality and Regulatory Director at Fiomi Diagnostics AB, she led the implementation of a certified quality management system and regulatory processes in both Europe and the United States.

“These key recruitments strengthen our management team, secure important positions for the upcoming company IPO, and lay the foundation for a successful market introduction of our DiviTum™ biomarker assay. DiviTum™ addresses a large unmet diagnostic need. Biovica will be able to provide great value for both patients and payers”, – Anders Rylander, CEO Biovica.

 

More information

Anders Rylander, CEO Biovica

Cell phone: +46 (0) 761 61 21 90
E-mail: anders.rylander@biovica.com

 

About Biovica

Biovica develops and commercializes blood-based biomarker assays that improve monitoring of modern cancer therapies and predict patient outcome. The company’s DiviTum™ assay, a test for accurately measuring cell proliferation, has successfully demonstrated its capabilities to early evaluate therapy effectiveness in several clinical trials. Biovica aims to make best-possible-treatment from day one a reality.

Biovica collaborates with world-leading cancer institutes as well as pharmaceutical companies launching next-generation therapies. The company is ISO 13485 certified for Quality Management Systems. DiviTum™ is CE-labeled and MPA-registered.

Read more: www.biovica.com

BIOVICA INTERNATIONAL AB
Uppsala Science Park
Dag Hammarskjölds väg 54 B
752 37 Uppsala, Sweden

2017-06-25T03:54:13+00:00 February 22nd, 2017 13:30|News|